IMCR vs. TWST, VCEL, DNLI, RXRX, APGE, IOVA, ACLX, ADMA, KYMR, and NVAX
Should you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Twist Bioscience (TWST), Vericel (VCEL), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), ADMA Biologics (ADMA), Kymera Therapeutics (KYMR), and Novavax (NVAX). These companies are all part of the "biological products, except diagnostic" industry.
Twist Bioscience (NASDAQ:TWST) and Immunocore (NASDAQ:IMCR) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
84.5% of Immunocore shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by insiders. Comparatively, 9.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Immunocore has a net margin of -22.60% compared to Immunocore's net margin of -69.24%. Twist Bioscience's return on equity of -16.54% beat Immunocore's return on equity.
Twist Bioscience received 39 more outperform votes than Immunocore when rated by MarketBeat users. However, 71.43% of users gave Immunocore an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Twist Bioscience has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
In the previous week, Immunocore had 9 more articles in the media than Twist Bioscience. MarketBeat recorded 15 mentions for Immunocore and 6 mentions for Twist Bioscience. Immunocore's average media sentiment score of 1.11 beat Twist Bioscience's score of 0.44 indicating that Twist Bioscience is being referred to more favorably in the media.
Immunocore has higher revenue and earnings than Twist Bioscience. Immunocore is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience presently has a consensus target price of $42.50, suggesting a potential downside of 1.57%. Immunocore has a consensus target price of $81.85, suggesting a potential upside of 79.53%. Given Twist Bioscience's higher possible upside, analysts clearly believe Immunocore is more favorable than Twist Bioscience.
Summary
Immunocore beats Twist Bioscience on 12 of the 18 factors compared between the two stocks.
Get Immunocore News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunocore Competitors List
Related Companies and Tools
